F m Investments LLC Reduces Stake in Prestige Consumer Healthcare Inc. $PBH

F m Investments LLC lowered its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 32.2% in the 4th quarter, HoldingsChannel reports. The fund owned 36,004 shares of the company’s stock after selling 17,103 shares during the period. F m Investments LLC’s holdings in Prestige Consumer Healthcare were worth $2,221,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the business. Profund Advisors LLC boosted its position in shares of Prestige Consumer Healthcare by 3.2% during the third quarter. Profund Advisors LLC now owns 6,770 shares of the company’s stock valued at $422,000 after buying an additional 207 shares during the period. Cerity Partners LLC boosted its position in shares of Prestige Consumer Healthcare by 5.9% during the second quarter. Cerity Partners LLC now owns 3,884 shares of the company’s stock valued at $310,000 after buying an additional 218 shares during the period. Diversify Advisory Services LLC boosted its position in shares of Prestige Consumer Healthcare by 4.6% during the third quarter. Diversify Advisory Services LLC now owns 5,837 shares of the company’s stock valued at $354,000 after buying an additional 256 shares during the period. Geneos Wealth Management Inc. boosted its position in shares of Prestige Consumer Healthcare by 92.8% during the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after buying an additional 269 shares during the period. Finally, Barrow Hanley Mewhinney & Strauss LLC boosted its position in shares of Prestige Consumer Healthcare by 106.8% during the third quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock valued at $34,000 after buying an additional 283 shares during the period. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Key Headlines Impacting Prestige Consumer Healthcare

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Oppenheimer kept an Outperform rating on PBH, even after trimming its price target to $65 from $77, suggesting the stock still has upside from recent levels. Article source
• Neutral Sentiment: Analysts continue to see a reasonable earnings trajectory for PBH, with consensus full-year EPS at $4.54 and Zacks projecting $4.76 for FY2027 and $5.05 for FY2028.
• Neutral Sentiment: A broader analyst note highlighted upcoming Q4 earnings expectations, but no new company guidance or major business update was reported in the article. Article source
• Negative Sentiment: Zacks Research cut EPS estimates for PBH, including lowering Q2 2028 estimates to $1.24 from $1.30 and trimming FY2027/FY2028 forecasts slightly, which can signal softer long-term expectations.
• Negative Sentiment: Insider selling added to the cautious tone: VP Jeffrey Zerillo sold shares in two May 5 transactions, including 1,207 shares and 346 shares, both disclosed under a pre-arranged trading plan.
• Negative Sentiment: PBH’s latest earnings report missed expectations, with EPS of $1.14 versus $1.16 expected and revenue of $283.44 million versus $286.93 million estimated, while revenue fell 2.4% year over year.

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare stock opened at $52.53 on Friday. The company has a 50 day moving average price of $60.23 and a 200-day moving average price of $61.92. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.93 and a current ratio of 3.11. Prestige Consumer Healthcare Inc. has a fifty-two week low of $51.24 and a fifty-two week high of $89.37. The company has a market capitalization of $2.49 billion, a PE ratio of 13.90, a P/E/G ratio of 1.58 and a beta of 0.40.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, February 5th. The company reported $1.14 earnings per share for the quarter, missing the consensus estimate of $1.16 by ($0.02). Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The company had revenue of $283.44 million for the quarter, compared to the consensus estimate of $286.93 million. During the same period in the prior year, the firm posted $1.22 EPS. The business’s revenue was down 2.4% on a year-over-year basis. As a group, equities analysts forecast that Prestige Consumer Healthcare Inc. will post 4.54 earnings per share for the current year.

Insider Buying and Selling at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 1,207 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total transaction of $66,372.93. Following the completion of the sale, the vice president owned 42,820 shares of the company’s stock, valued at approximately $2,354,671.80. The trade was a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold a total of 2,553 shares of company stock worth $151,444 over the last ninety days. Insiders own 1.40% of the company’s stock.

Wall Street Analysts Forecast Growth

PBH has been the subject of several recent analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Tuesday, April 21st. Jefferies Financial Group dropped their target price on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research report on Friday, January 30th. Finally, Oppenheimer dropped their target price on Prestige Consumer Healthcare from $77.00 to $65.00 and set an “outperform” rating for the company in a research report on Thursday. Three equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $74.75.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).